AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Achieve Life Sciences, Inc.
XNAS · usd
SIC 2835 · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
FIGI BBG001S8JF14
6.49▼ 0.01 (-0.15%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
6.50
Day's Range
6.36 – 6.61
52-Week Range
2.62 – 8.64
Volume
582.4K
Avg Volume
1.5M
Share Statistics
Shares Outstanding
Employees
28
Exchange
XNAS
Listed
1995-10-12
Share count as of August 11, 2026

Achieve Life Sciences, Inc. (ACHV) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Achieve Life Sciences, Inc. (ACHV)
What is Achieve Life Sciences, Inc.'s Market Cap?
Achieve Life Sciences, Inc.'s Market Cap is $667.8M, based on as-reported figures from SEC (XBRL) filings.
What is Achieve Life Sciences, Inc.'s Enterprise Value?
Achieve Life Sciences, Inc.'s Enterprise Value is $480.5M, based on as-reported figures from SEC (XBRL) filings.
What is Achieve Life Sciences, Inc.'s Net Income (TTM)?
Achieve Life Sciences, Inc.'s Net Income (TTM) is -$114.0M, based on as-reported figures from SEC (XBRL) filings.
What is Achieve Life Sciences, Inc.'s Diluted EPS (TTM)?
Achieve Life Sciences, Inc.'s Diluted EPS (TTM) is -1.11, based on as-reported figures from SEC (XBRL) filings.
What is Achieve Life Sciences, Inc.'s Net Debt?
Achieve Life Sciences, Inc.'s Net Debt is -$187.3M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ACHVAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
EXPENSES
Research and development—
Research and development - related parties [note 8]———
General and administrative—
General and administrative - related parties [note 8]———
Total operating expenses—
OTHER INCOME
Interest income—
Interest expense [note 6]—
Change in fair value of contingent consideration [note 4 and note 5]—
Loss on extinguishment of 2023 SVB convertible term loan [note 6]————
Other (expenses) income—
Warrant issuance cost [note 7b]———
Change in fair value of warrant liability [note 5]———
Change in fair value of pre-funded warrant liability [note 5]———
Total other income—
Net loss
Basic net loss per common share [note 7[d]]—
Diluted net loss per common share [note 7[d]]—